3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
CNS
1
Conditions
Glioblastoma
49
Brain Neoplasms
25
Central Nervous System Neoplasms
22
Astrocytoma
17
Glioma
15
Medulloblastoma
11
Neoplasms
8
Oligodendroglioma
7
Recurrence
6
Gliosarcoma
6
Spinal Cord Neoplasms
2
Ependymoma
2
Sarcoma
1
Pancreatic Neoplasms
1
Optic Nerve Glioma
1
Newly Diagnosed High Grade Glioma
1
Neuroectodermal Tumors, Primitive
1
Neuroectodermal Tumors
1
Neoplasm Recurrence, Local
1
Neoplasm Metastasis
1
Melanoma
1
Lymphoma, Non-Hodgkin
1
Lymphoma, Follicular
1
Lung Neoplasms
1
Leukemia-Lymphoma, Adult T-Cell
1
Kidney Neoplasms
1
Hereditary Sensory and Autonomic Neuropathies
1
Familial ependymoma
1
Drug-Related Side Effects and Adverse Reactions
1
Diffuse Intrinsic Pontine Glioma
1
Interventions
Temozolomide
2
Oncolytic Virotherapy
2
vorasidenib
1
pembrolizumab
1
pamiparib
1
interferon gamma-1b
1
cixutumumab
1
Vorinostat
1
Vincristine
1
Valproic Acid
1
Thiotepa
1
Radiotherapy
1
Radiation
1
Peripheral Blood Stem Cell Transplantation
1
ONC206
1
Melphalan
1
Maintenance Chemotherapy
1
Lomustine
1
Interleukin-12
1
Interferon-gamma
1
Immunotherapy
1
Granulocyte Colony-Stimulating Factor
1
Filgrastim
1
Etoposide
1
Erlotinib Hydrochloride
1
Cisplatin
1
Busulfan
1
Bone Marrow Transplantation
1
Antibodies, Monoclonal
1
Aminolevulinic Acid
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Neuroectodermal Tumors
×
Lomustine
×
CNS
×
Clear all
NCT01614132
2020-03-31
NOA-07
University of Regensburg
Phase 1/2
Completed
33 enrolled